Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant

NCT00241345 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

39

Enrollment

OTHER

Sponsor class

Stopped Due to low accrual

Conditions

Cytomegalovirus Infections

Interventions

DRUG: Valganciclovir
DRUG: Ganciclovir

Sponsor

Washington University School of Medicine